Bon Giulia, Folgiero Valentina, Bossi Gianluca, Felicioni Laura, Marchetti Antonio, Sacchi Ada, Falcioni Rita
Molecular Oncogenesis Laboratory, Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3280-7. doi: 10.1158/1078-0432.CCR-05-2223.
The alpha6beta4 integrin, a laminin receptor, has been implicated from many studies in tumor progression and invasion. We showed that the beta4 integrin subunit associates with the ErbB-2 tyrosine kinase in human mammary carcinoma cell lines and that its overexpression in NIH3T3/ErbB-2-transformed cells causes a constitutive activation of phosphatidylinositol 3-kinase (PI3K), inducing a strong increase of their invasive capacity. In this study, we investigated the biological consequences of interference with the endogenous beta4 integrin subunit expression.
In vitro and in vivo tumor growth and the biochemical consequences of beta4 integrin inactivation were studied in mammary tumor cells by using short hairpin RNA approach.
Our data show that tumor growth of mammary tumor cells strictly depends on beta4 expression, confirming the relevance of beta4 protein in these cells. Moreover, interference with beta4 expression significantly reduces endogenous PI3K activity and AKT and mammalian target of rapamycin phosphorylation. Accordingly, with these results and considering that PI3K activity in mammary tumor plays a relevant role in hormone resistance, we asked whether beta4 expression might be relevant for hormone responsiveness in these cells. Data reported indicate that the interference with endogenous beta4 expression, upon hormone deprivation, induces caspase-9 and cytochrome c-mediated apoptosis, which is enhanced upon tamoxifen treatment. On the other hand, the expression of myr-AKT in MCF7 beta4-short hairpin RNA cells rescues the cells from apoptosis in the absence of hormones and upon tamoxifen treatment.
Overall, these results confirm the relevance of beta4 expression in mammary tumors and indicate this integrin as a relevant target for tumor therapy.
α6β4整合素是一种层粘连蛋白受体,许多研究表明其与肿瘤进展和侵袭有关。我们发现β4整合素亚基与人乳腺癌细胞系中的ErbB-2酪氨酸激酶相关,并且其在NIH3T3/ErbB-2转化细胞中的过表达导致磷脂酰肌醇3激酶(PI3K)的组成性激活,从而使其侵袭能力显著增强。在本研究中,我们研究了干扰内源性β4整合素亚基表达的生物学后果。
通过短发夹RNA方法研究乳腺肿瘤细胞的体外和体内肿瘤生长以及β4整合素失活的生化后果。
我们的数据表明,乳腺肿瘤细胞的肿瘤生长严格依赖于β4的表达,证实了β4蛋白在这些细胞中的相关性。此外,干扰β4表达可显著降低内源性PI3K活性以及AKT和雷帕霉素哺乳动物靶点的磷酸化水平。基于这些结果,并考虑到乳腺肿瘤中的PI3K活性在激素抵抗中起相关作用,我们询问β4表达是否可能与这些细胞中的激素反应性相关。报道的数据表明,在激素剥夺后干扰内源性β4表达会诱导caspase-9和细胞色素c介导的凋亡,而他莫昔芬治疗会增强这种凋亡。另一方面,在MCF7 β4短发夹RNA细胞中表达myr-AKT可使细胞在无激素和他莫昔芬治疗时免于凋亡。
总体而言,这些结果证实了β4表达在乳腺肿瘤中的相关性,并表明这种整合素是肿瘤治疗的相关靶点。